Drug intelligence / Profile preview

PD1-TIL

Development stage: Phase 1
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Intratumoral

Overview

PD1-TIL is an adoptive cell therapy utilizing genetically modified tumor-infiltrating lymphocytes (TILs). These TILs are engineered to stably express a high-level, full-length PD1 antibody. This modification enables the PD1-TIL cells to transduce signals that activate T cells, ultimately leading to tumor cell killing. The therapy is being investigated for its safety and efficacy in treating solid tumors, such as glioblastoma multiforme.

Other names: genetically modified TILs

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on PD1-TIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD1-TIL.

Explore the full profile